Drug Profile
Research programme: immunoproteasome inhibitors - Kezar Life Sciences
Latest Information Update: 28 Jul 2019
Price :
$50
*
At a glance
- Originator Onyx Pharmaceuticals
- Developer Kezar Life Sciences
- Class Small molecules
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Jul 2019 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 16 Jun 2015 Early research in Autoimmune disorders in USA (unspecified route)